The Adult Spasticity International Registry (ASPIRE) Study: 1-Year Results (P4.034)

Conclusions:Findings demonstrate the real-world safety and effectiveness for onabotulinumtoxinA treatment in spasticity. Further analyses will explore clinical and burden outcomes and differences across etiology and presentation.Study Supported by: Allergan plcDisclosure: Dr. Francisco has received personal compensation for activities with Allergan, Ipsen, Mallinckrodt, and Merz. Dr. Francisco has received personal compensation in an editorial capacity for Journal of Rehabilitation Medicine. Dr. Francisco has received research support from Allergan, Ipsen, Mallinckrodt, Medtronic, Merz, Microtransponder, and Nexstim. Dr. Bandari has received personal compensation for activities with Accorda Therapeutics Biogen, Genzyme, Mallinckrodt, Serono, and Teva Neuroscience as a speaker bureau/copns.ant. Dr. Bandari has received research support from Allergan, Biogen, Genentech, and Genzyme. Dr. Bavikatte has received personal compensation for activities with Allergan, Merz, Ipsen and Grunenthal. Dr. Jost has received personal compensation for activities with Abbvie, Allergan, Bial, Desitin, Ipsen, Merz, and Zambon as a speaker and/or consultant. Dr. Manack Adams has received personal compensation for activities with Allergan as an employee. Dr. Manack Adams holds stock and or stock options in Allergan as an employee. Dr. Largent has received personal compensation for activities with QuintilesIMS as an employee. Dr. Esquenazi has received personal compensation for activities with IPSEN ...
Source: Neurology - Category: Neurology Authors: Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research